Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Watson Begins Anew As Actavis, Focuses On Organic Growth

This article was originally published in The Pink Sheet Daily

Executive Summary

The traditionally generic-heavy company now has an expanded global presence and a growing branded business to go with its new name.

You may also be interested in...



Teva Reorganizes With Emphasis On Strengthening Generics

Former Actavis Pharma President Olafsson has been appointed president and CEO of the newly formed Global Generic Medicines Group, which will consolidate Teva’s regional generic businesses under one group.

Teva CEO Suits Up For Acquisitions As A Springboard For Growth

In his first public comments to investors, CEO Erez Vigodman said he will consider large acquisitions to drive growth at Teva, while deepening cost cuts and refocusing on generics to maintain Teva’s leadership position.

Teva CEO Vigodman Reveals A First Glimpse At His Strategy

Teva’s new CEO addressed investors publicly for the first time May 1 and discussed his initial thoughts on plans to turn around the generic drug leader. Those include deeper cost cuts, a renewed emphasis on generic drugs and biosimilars, and potentially a large acquisition.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1129949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel